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ABSTRACT Group A streptococcus (GAS) species cause bacterial pharyngitis in both
adults and children. Early and accurate diagnosis of GAS is important for appropriate
antibiotic therapy to prevent GAS sequalae. The Revogene Strep A molecular assay
(Meridian Bioscience Canada Inc, Quebec City, QC, Canada) is an automated realtime PCR assay for GAS detection from throat swab specimens within approximately
70 min. This multicenter prospective study evaluated the performance of the Revogene Strep A molecular assay compared to that of bacterial culture. Dual throat
swab specimens in either liquid Amies or Stuart medium were collected from eligible subjects (pediatric population and adults) enrolled across 7 sites (USA and Canada). Revogene Strep A and reference testing was performed within 7 days and 48 h
of sample collection, respectively. Of the 604 evaluable specimens, GAS was detected in 154 (25.5%) samples by the reference method and in 175 (29%) samples
by the Revogene Strep A assay. Revogene Strep A assay sensitivity and speciﬁcity
were reported to be 98.1% (95% conﬁdence interval [CI], 94.4 to 99.3) and 94.7%
(95% CI, 92.2 to 96.4), respectively. The positive predictive value was 86.3% (95% CI,
80.4 to 90.6), negative predictive value was 99.3% (95% CI, 98.0 to 99.8) with a 1.0%
invalid rate. Discrepant analysis with alternative PCR/bidirectional sequencing was
performed for 24 false-positive (FP) and 3 false-negative (FN) specimens. Concordant
results were reported for 17 (FP only) of 27 discordant specimens. The Revogene
Strep A assay had high sensitivity and speciﬁcity for GAS detection and provides a
faster alternative for GAS diagnosis.
KEYWORDS clinical trial, group A streptococcus, molecular assay, multicenter

A

cute pharyngitis, although primarily of viral etiology, is also caused by Streptococcus pyogenes, a member of the group A streptococcus (GAS) by Lanceﬁeld serogrouping and is more commonly isolated in children between 3 and 15 years of age (1).
GAS species are isolated in up to 37% of sore throat episodes in children older than 5
years (2, 3), whereas their prevalence in adult patients is estimated to be in the range
of 5% to 10% (4). GAS presents with a wide spectrum of diseases that ranges from
uncomplicated pharyngitis and skin infections to severe sepsis, toxic shock syndrome,
and necrotizing fasciitis. Nonsuppurative sequalae of GAS infection, mainly acute
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glomerulonephritis (AGN) and acute rheumatic fever (ARF), account for signiﬁcant
cause of global morbidity and mortality, with a particular impact in resource-limited
settings (5, 6). Annually, 500,000 people worldwide develop ARF, with 223,000 deaths
reported each year that are directly attributed to ARF or to subsequent rheumatic heart
disease (7, 8). However, in more afﬂuent countries, the majority of S. pyogenesassociated deaths are associated with invasive disease (5). Accurate diagnosis and
prompt initiation of antibiotic therapy are essential for treatment and prevention of
sequalae.
Current guidelines for diagnosis of GAS pharyngitis in children and adolescents
recommend the testing of throat swab specimens by a rapid antigen detection test
(RADT) with a follow-up of RADT-negative specimens by culture (9). Routine backup
with culture is not recommended in adults with a negative RADT result because of the
low incidence of sequelae of pharyngitis in this population (9). RADT assays are easy to
perform and have a rapid turnaround time (TAT; ⬍15 min) with high speciﬁcity (95%).
However, the relatively low sensitivity (70 to 90%) of RADTs prompts the need for a
backup culture in the RADT-negative specimens from children and young adults (3, 10,
11). Bacterial culture, the gold standard method, is both highly sensitive and speciﬁc (90
to 95%), but is labor-intensive and requires a minimum of 24 to 48 h for reporting a
positive result (12). More recently, nucleic acid ampliﬁcation testing (NAAT) assays have
become popular due to their enhanced sensitivity and speciﬁcity and faster TAT (13).
Implementation of PCR as a stand-alone diagnostic test for GAS in a clinical setting has
led to a signiﬁcant increase in positive laboratory test results (14). Prompt and appropriate methods of testing can help lower the incidence of inappropriate antibiotic use,
mainly in patients with viral pharyngitis. However, correct patient selection is important
to limit low levels of GAS detection by highly sensitive PCRs in asymptomatic carriers
(15). The use of molecular assays for detecting GAS pharyngitis could be an important
addition to the guidelines.
The recently Food and Drug Administration (FDA)-cleared Revogene Strep A molecular assay, performed on the Revogene instrument, is an automated, qualitative,
moderately complex in vitro diagnostic test that detects GAS nucleic acids directly from
throat swab specimens by real-time PCR (RT-PCR). The Revogene instrument is capable
of automated cell lysis, dilution of nucleic acids, automated ampliﬁcation, and detection
of target nucleic acid sequences in as few as 42 min for GAS-positive and 70 min for
GAS-negative samples. In this multicenter study, we evaluated the clinical performance
of the Revogene Strep A assay in detecting GAS from throat swab specimens prospectively collected from subjects with pharyngitis.
MATERIALS AND METHODS
Study design. This prospective multicenter study was conducted between February 2018 and July
2018 at 7 geographically diverse sites across the United States (Missouri, California, Michigan, Indiana,
and Wisconsin) and Canada (British Columbia and Quebec). There was one reference center in each
country, namely Texas in the United States and British Columbia in Canada. Throat swab specimens were
collected from subjects in accordance with site-speciﬁc institutional review board-approved protocols.
Inclusion criteria were (i) patients presenting with signs and symptoms of pharyngitis, (ii) informed
consent obtained from subject or legal guardian, (iii) patient was older than 2 years of age, and (iv)
patient provided a dual swab in either liquid Stuart or liquid Amies transport medium. Exclusion criteria
were (i) use of antibiotics within 7 days prior to specimen collection and (ii) any specimen not compliant
with the study protocol.
Specimens. Specimens from subjects ⬎2 years of age with signs and symptoms of pharyngitis were
enrolled. Demographic information about subjects from different sites is listed in Table 1. Dual throat
swab specimens were collected using Copan (Italy) or BD swabs. The swab heads were rubbed together
for uniform sampling; one swab was broken off and placed in the Sample buffer tube (SBT) to test with
the Revogene Strep A assay at the collection center, while the second swab was placed in transport
medium (liquid Amies for Quebec, Michigan, Indiana, and Missouri sites and liquid Stuart medium for
British Columbia, Wisconsin, and California sites) and shipped to the reference centers for reference
method testing. Samples for reference testing were sent to the respective Canadian or American
reference centers at 2° to 8°C within 48 h of collection. Culture for retrieval of Streptococcus was initiated
within 72 h of collection. The specimen in SBT was stored at 2° to 8°C and tested at the collection sites
within 7 days on the Revogene Strep A assay. After obtaining a valid result or following a single repeat
test, an aliquot of SBT was prepared and stored at ⫺20°C or colder and was shipped to the sponsor
periodically.
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TABLE 1 Site-wide distribution of specimens and GAS prevalence by reference culture
No. (%) of specimens from site:
1 (n ⴝ 69)

2 (n ⴝ 67)

3 (n ⴝ 42)

4 (n ⴝ 123)

5 (n ⴝ 178)

6 (n ⴝ 49)

7 (n ⴝ 76)

Total

53 (76.8)
15 (21.7)
1 (1.5)
0 (0.0)

0 (0.0)
4 (5.9)
62 (92.5)
1 (1.6)

0 (0.0)
5 (11.9)
32 (76.2)
5 (11.9)

114 (92.7)
7 (5.7)
1 (0.8)
1 (0.08)

12 (6.7)
24 (13.5)
138 (77.5)
4 (2.3)

40 (81.6)
9 (18.4)
0 (0.0)
0 (0.0)

59 (77.6)
16 (21)
1 (1.4)
0 (0.0)

278 (46)
80 (13.2)
235 (38.9)
11 (1.8)

Ethnicity
White
Hispanic
Black/African American
Asian
Unknown

0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
69 (100)

60 (89.5)
4 (5.9)
1 (1.6)
1 (1.6)
1 (1.6)

21 (50)
0 (0.0)
20 (47.6)
1 (2.4)
0 (0.0)

18 (14.6)
8 (6.5)
93 (75.6)
1 (0.8)
3 (2.4)

59 (33.1)
21 (11.8)
89 (50)
0 (0.0)
9 (5.1)

15 (30.6)
10 (20.4)
24 (49)
0 (0.0)
0 (0.0)

15 (19.7)
53 (69.7)
3 (3.9)
2 (2.6)
3 (3.9)

188 (31.1)
96 (15.9)
230 (37.9)
5 (0.8)
85 (14.1)

GAS culture result
Positive
Negative

16 (23.2)
53 (76.8)

18 (26.9)
49 (73.1)

2 (4.8)
40 (95.2)

59 (48)
64 (52)

30 (16.9)
148 (24.5)

13 (26.5)
36 (73.5)

16 (21.1)
60 (78.9)

154 (25.5)
450 (74.5)

Revogene Strep A assay. The broken swab in SBT was processed on the Revogene within 7 days of
collection. A set of environmental controls were run at the beginning of the study, following which
external positive and negative controls were run each day samples were tested by the Revogene Strep
A assay. Sample testing involved adding a designated amount of SBT (120 l to 200 l) to the disposable
microﬂuidic cartridges (PIE), which were then loaded onto the Revogene instrument. Up to 8 samples
could be tested on the Revogene simultaneously. The ampliﬁed products were detected in real time
using target-speciﬁc TaqMan chemistry-based probes. On completion of a run, the results were computed by the system from measured ﬂuorescent signals and embedded calculation algorithms. Samples
that initially produced a nonreportable result (unresolved, indeterminate or external control [EC] failure)
were repeat tested following instructions from the package insert. Samples with a reportable (positive,
negative) result upon repeat testing were included in the data analyses.
Reference testing. Samples for reference testing were cultured on blood agar plates (BAP) and
incubated for 24 to 48 h at 35° to 37°C under 5% CO2 or anaerobic conditions. Colonies morphologically
resembling Streptococcus pyogenes (GAS) were isolated on a new BAP and reincubated for 24 h under
similar conditions before proceeding to identiﬁcation tests. Identiﬁcation was conﬁrmed by catalase test
(nonreactive), Gram staining (Gram-positive cocci in chains), presence of beta hemolysis, and a GASspeciﬁc latex agglutination test. Isolated colonies identiﬁed as GAS by latex were distributed into 2
aliquots and frozen for additional testing at the reference centers. Frozen isolated colonies were thawed,
plated on BAP, and further characterized using matrix-assisted laser desorption ionization-time of ﬂight
mass spectroscopy (MALDI-TOF MS) identiﬁcation at the U.S. reference center. The Canadian reference
center processed samples, including culture and colony identiﬁcation, following which the frozen
aliquots were shipped to the U.S. reference center for MALDI-TOF MS.
Discordant analysis. Specimens with discordant ﬁndings between the Revogene Strep A assay and
reference method were further analyzed by alternative PCR/bidirectional sequencing. Sample buffer
leftover from the Revogene Strep A test was frozen without the swab and sent to the Centre de
Recherche en Infectiologie, where the sample buffer underwent mechanical and thermal lysis and was
mixed with the PCR reagents. PCR was performed on the CFX96 (Bio-Rad) instrument, targeting a
proprietary GAS-speciﬁc gene other than the target used in Revogene Strep A assay. If PCR led to an
ampliﬁcation, the amplicon was puriﬁed and sent for bidirectional sequencing.
Statistical analysis. (i) Sample size calculation. With the average prevalence of Streptococcus
pyogenes in clinical specimens at 20% in North America, at least 600 samples needed be enrolled to
achieve the study objective of 120 samples positive for GAS by reference method.
(ii) Descriptive analysis. Overall GAS prevalence was determined by each site and age group.
(iii) Analytical statistics. Revogene data were analyzed using software v4.0.10 and assay deﬁnition
ﬁle v0.2.1. Performance characteristics (sensitivity, speciﬁcity, positive predictive value [PPV], and negative predictive value [NPV]) of the Revogene Strep A assay in comparison to those of the reference
method were calculated using two-by-two tables. Data are presented as value ⫾ 95% conﬁdence
intervals (CI). Conﬁdence intervals were determined using the Wilson scoring method. The invalid rate
was determined based on samples that resulted as either “unresolved” (due to sample inhibitors or
failure of internal positive control to amplify) or “indeterminate” (instrument failure).

RESULTS
A total of 767 unique throat swab specimens were collected in the study period
across 7 sites, of which 163 (21.3%) specimens were excluded from performance
calculations. Exclusions were primarily due to (i) deviation from reference method
culture protocol (100, 61.3%), (ii) erroneous PCR results (due to external control failure,
July 2020 Volume 58 Issue 7 e01775-19
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Patient characteristic
Age
24 mo–12 yrs
13–21 yrs
22–64 yrs
⬎65 yrs
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TABLE 2 Clinical performance of the Revogene Strep A assaya
Bacterial culture plus MALDI-TOF MS results
(no.)
Revogene Strep A assay result
Positive
Negative
Total

Positive
151
3
154

Negative
24
426
450

Total
175
429
604

aSensitivity

and speciﬁcity of the Revogene Strep A assay were 98.1 (95% CI, 94.4 to 99.3) and 94.7 (95% CI,
92.2 to 96.4), respectively, and the PPV and NPV were 86.3 (95% CI, 80.4 to 90.6) and 99.3 (95% CI, 98.0 to
99.8), respectively.

Downloaded from http://jcm.asm.org/ on July 14, 2020 by guest

deviations from package insert instructions, or indeterminate/unresolved results after
repeat testing) (13, 8.0%), (iii) deviations based on transport and storage time/conditions (13, 7.9%), (iv) patients missing PCR or reference method results (13, 8.0%), (v)
specimens collected outside clinical approval (11, 6.7%), (vi) patients younger than
24 months old (6, 3.7%), (vii) patients using antibiotics (3, 1.8%), (viii) patients enrolled
after the study period (2, 1.2%), and (ix) duplicate specimens (2, 1.2%). Overall, 604
evaluable specimens were included, with individual sites providing between 7% and
29.5% of the total study samples. The majority of the enrolled subjects were within 2
to 12 years old (278, 46%), followed by patients ranging between 22 to 64 years (235,
38.9%). Detailed patient demographic information is provided in Table 1.
Of the 604 unique samples that were evaluated, 175 (29.0%) were reported as
positive by the Revogene Strep A assay. Eleven specimens yielded either “unresolved”
(n ⫽ 3) or “indeterminate” (n ⫽ 8) results in the initial run, demonstrating an initial
invalid rate of 1.8% (11/610). After repeat testing, only 6 specimens yielded “unresolved” (n ⫽ 1) or “Indeterminate” (n ⫽ 5) results, resulting in a ﬁnal invalid rate of 1.0%
(6/610). Reference culture tested positive for 154 samples (25.5%). Site-wide GAS
prevalence by reference culture is demonstrated in Table 1. The Revogene Strep A assay
showed a sensitivity and speciﬁcity of 98.1% (95% CI, 94.4 to 99.3) and 94.7% (95% CI,
92.2 to 96.4), respectively (Table 2). The PPV was reported to be 86.3 (95% CI, 80.4 to
90.6), while the NPV was 99.3 (95% CI, 98.0 to 99.8). Three (3) specimens were false
negative (FN) and 24 specimens were false positive (FP) by Revogene Strep A assay
compared to reference culture.
Discrepant analysis was performed on 27 specimens by retesting a frozen aliquot
from the sample buffer tube at a third-party facility (Centre de Recherche en Infectiologie de Quebec) by an alternative PCR assay followed by bidirectional sequencing
(Table 3). Results were reported as positive, negative, or inconclusive (sequence could
not be reported due to poor quality). Of the 24 FP samples, the majority were from
subjects aged 24 months to 12 years old (14/24, 58.3%), followed by subjects who were
22 to 64 years old (7/24, 29.2%). In total, 17/24 specimens (70.8%) that were FP by
Revogene Strep A assay were positive for GAS by discrepant testing, while 1/24
provided inconclusive result. A total of 6/24 FP results were negative for GAS. One of
the 3 specimens (33.3%) that were FN with Revogene Strep A assay was positive for
GAS by discrepant testing. However, the remaining 2 specimens remained inconclusive.

TABLE 3 Discrepant analysis of Revogene Strep A assay compared to culture
No. of
samples
17
6
1
2
1
aFP,

Revogene
assay result
Positive
Positive
Positive
Negative
Negative

Culture plus
MALDI-TOF
MS result
Negative
Negative
Negative
Positive
Positive

Result
typea
FP
FP
FP
FN
FN

PCR result/
sequencing assay
Positive
Negative
Inconclusive
Inconclusive
Positive

false positive; FN, false negative.
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DISCUSSION
The gold standard for diagnosis of GAS pharyngitis is the isolation of bacteria on a
48-h culture (1). However, due to the associated time lag between sample collection
and test results and the labor intensiveness of the procedures involved, faster and
easier alternatives such as RADTs are more commonly employed for detecting GAS.
Most of these assays report a high speciﬁcity, ruling out the need for a backup culture
in a positive RADT result (12, 13). However, the currently available RADTs lack sensitivity, potentially leading to missed diagnosis of true GAS infection in patients (11, 16,
17). The need for highly sensitive and rapid assays to compete against the more
time-consuming culture methods and less sensitive RADTs led to the development of
molecular assays. These assays demonstrate superior sensitivity compared to RADTs
without a loss of speciﬁcity, and they eliminate the need for culture conﬁrmation,
making them an attractive option for laboratory diagnosis of GAS (13, 14, 18).
Several FDA-approved nucleic acid ampliﬁcation assays are available and include
(Clinical Laboratory Improvement Amendments) CLIA waived and CLIA moderate complexity tests (13). These assays are based on a number of different principles that range
from real-time PCR detection to loop-mediated isothermal ampliﬁcation (LAMP) in the
illumigene assay (Meridian BioScience) and isothermal helicase-dependent ampliﬁcation (HDA) in the Solana GAS and Solana Strep Complete assays (Quidel Corp.). The
Simplexa Group A Strep direct kit (Diasorin Molecular), Cobas Strep A assay (Roche
Diagnostics), Aries Group A Strep assay (Luminex Corporation), Lyra Direct Strep (Quidel
Corporation), and Xpert Xpress Strep A (Cepheid) are real-time PCR assays that target
different conserved regions of the GAS genome (sdaB, speB, spy1258, or comx1.1 genes)
(13). Previous studies on respective platforms have demonstrated high sensitivities and
speciﬁcities (13, 19–24). The ID Now Strep A 2 assay (Abbott lab) is based on the
principle of isothermal nicking enzyme ampliﬁcation reaction (NEAR) (18, 25) and has
comparable performance. In addition to the high diagnostic performance, the Xpert
Xpress, Cobas Strep A, and ID Now Strep A 2 assays are point-of-care systems that are
easy to perform and exhibit a TAT ranging between 6 and 24 min, which has made
them increasingly popular.
This is the ﬁrst study to evaluate the performance characteristics of the recently
developed Revogene Strep A assay compared to reference culture and MALDI-TOF MS
identiﬁcation. Results from our study demonstrated comparable sensitivity and speciﬁcity to other molecular assays (⬎94% for both) for detecting GAS in throat swabs from
patients with acute pharyngitis. Of the 3 specimens that tested negative (FN) on
Revogene Strep assay compared to culture, one was negative by alternative PCR/
bidirectional sequencing assay as well, and 2 specimens were inconclusive, suggesting
the presence of a potential inhibitor in the sample itself that was interfering with the
ampliﬁcation. Of the 24 apparent false positives, 17/24 tested positive by alternative
methods, which might be due to the presence of GAS nucleic acids only (in the absence
of viable organisms) from patients with resolving infections or who are already undergoing antimicrobial therapy (26). Furthermore, the Revogene Strep A assay, being
highly sensitive, might detect very low levels of bacterial load in samples that were
otherwise negative by culture (14). In the analytical assessments in this study, 599/610
samples gave valid results in the initial run, and 5/11 samples with invalid initial results
demonstrated valid outcomes on repeat testing.
In addition to high sensitivity and speciﬁcity and low error/invalid rates, the Revogene Strep A assay is also easy to perform and requires minimum hands-on time
(approximately 3 min per sample). Revogene TAT is approximately 70 min for negative
and as short as 42 min for positive samples, thereby enabling physicians to initiate
appropriate treatment promptly. Simultaneous processing and testing of up to 8
samples provides the ﬂexibility to the operators for either batch testing or sequential
determinations. Testing can also be performed multiple times a day in laboratories with
high throughput. Accurate results due to the high sensitivity/speciﬁcity of the assay
jcm.asm.org 5
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bypass the need for culture conﬁrmation and could be used as the standalone
conﬁrmatory diagnostic method for diagnosing GAS pharyngitis.
Overall, the Revogene Strep A assay is highly sensitive and speciﬁc, easy to perform,
and provides reproducible results among different users in different clinical settings.
These aspects make it a useful diagnostic tool and an attractive alternative to other
rapid diagnostic tests for GAS pharyngitis.
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